Traci Umberger Sells 10,500 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 10,500 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the sale, the insider directly owned 136,633 shares in the company, valued at $3,646,734.77. The trade was a 7.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kestra Medical Technologies Price Performance

NASDAQ:KMTS opened at $26.52 on Friday. The firm has a market capitalization of $1.55 billion and a price-to-earnings ratio of -8.37. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.47 and a quick ratio of 5.47. The business has a 50 day simple moving average of $26.31 and a 200-day simple moving average of $21.44. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $30.00.

Wall Street Analyst Weigh In

KMTS has been the topic of several recent analyst reports. BTIG Research started coverage on shares of Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. The Goldman Sachs Group raised their price objective on shares of Kestra Medical Technologies from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Saturday, December 13th. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Sunday, September 28th. Finally, Stifel Nicolaus set a $30.00 price target on Kestra Medical Technologies in a research note on Friday, December 12th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.14.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP purchased a new position in shares of Kestra Medical Technologies during the first quarter worth approximately $33,000. Adage Capital Partners GP L.L.C. purchased a new position in Kestra Medical Technologies during the 1st quarter worth $2,492,000. Alyeska Investment Group L.P. bought a new stake in Kestra Medical Technologies during the 1st quarter valued at $2,492,000. Alliancebernstein L.P. purchased a new stake in shares of Kestra Medical Technologies in the 1st quarter worth $29,500,000. Finally, Eventide Asset Management LLC bought a new position in shares of Kestra Medical Technologies during the 1st quarter worth $6,853,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.